![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H22N2O |
Molar mass | 234.343 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development. [1]
It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms [2] [3]
Ispronicline is subtype-selective, binding primarily to the α4β2 subtype. It has antidepressant, nootropic and neuroprotective effects.[ medical citation needed ]
Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache. [4] [5] [6] [7] [8] However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug. [1]